Status:
TERMINATED
Neuroprotection of Pioglitazone in Acute Ischemic Stroke
Lead Sponsor:
Taipei Medical University Shuang Ho Hospital
Conditions:
Stroke
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Pioglitzone, an oral anti-diabetic drug which can reduce insulin resistance and decrease inflammation. It has been proven to be an effective neuroprotective agent in animal model of ischemic stroke. I...
Eligibility Criteria
Inclusion
- Acute ischemic stroke onset within 48 hours
- Age≧20 years
- Stroke severity with at least one point for limb weakness in National Institutes of Health Stroke Scale (NIHSS).
- The patients with no known history of diabetes with admission serum glucose ≧130 mg/dl.
Exclusion
- The patients who have history of urinary bladder cancer or hematuira.
- The patients who have history of congestive heart failure or myocardial infarction.
- The patients who have known history of using pioglitazone before the onset of stroke.
- The patients who have mRS≧3 before stroke onset.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT02195791
Start Date
July 1 2014
End Date
August 1 2016
Last Update
January 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Medical Universtiy- Shuang Ho Hospital
New Taipei City, Taiwan, 235